Anti-Coagulants - United Arab Emirates

United Arab Emirates

The Anti-Coagulants market in the United Arab Emirates is expected to witness significant revenue growth, with projected revenue reaching US$59.25m in 2024.
This growth is anticipated to continue at a steady pace, with an annual growth rate (CAGR 2024-2029) of 8.64%.
By 2029, the market volume is expected to expand to US$89.65m.
In comparison to other countries, United States is projected to generate the highest revenue in the Anti-Coagulants market, with an estimated revenue of US$16,740.00m in 2024.
The demand for anti-coagulants in the United Arab Emirates is rising steadily due to the increasing prevalence of cardiovascular diseases in the country.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in United Arab Emirates has been showing steady growth in recent years.

Customer preferences: The customers in the UAE are becoming more health-conscious and aware of the benefits of preventative healthcare. This has led to an increase in demand for Anti-Coagulants, which are used to prevent blood clots and reduce the risk of stroke or heart attack.

Trends in the market: One of the main trends in the Anti-Coagulants market in the UAE is the increasing use of novel oral anticoagulants (NOACs). These drugs have several advantages over traditional anticoagulants, including a lower risk of bleeding and fewer drug interactions. The demand for NOACs is expected to continue to grow in the coming years.Another trend in the market is the increasing use of point-of-care testing (POCT) devices for monitoring anticoagulation therapy. These devices allow patients to monitor their blood clotting levels at home, reducing the need for frequent visits to the doctor's office or hospital.

Local special circumstances: The UAE has a high prevalence of cardiovascular disease, which is one of the main drivers of demand for Anti-Coagulants. Additionally, the country has a large expatriate population, many of whom come from countries with a high prevalence of thrombotic disorders.

Underlying macroeconomic factors: The UAE has a rapidly growing healthcare sector, with the government investing heavily in healthcare infrastructure and services. This has led to an increase in the availability and accessibility of healthcare services, including Anti-Coagulants. Additionally, the country has a high per capita income, which allows for greater spending on healthcare.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.